Intermediate‐grade lymphomas treated with cyclophosphamide‐doxorubicin‐vincristine‐prednisone‐bleomycin alternated with cyclophosphamide‐methotrexate‐etoposide‐dexamethasone. Application of prognostic models to data analysis